HAE vs PATH
Haemonetics Corporation (HAE) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Haemonetics Corporation (HAE) is a medical devices company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported HAE revenue for 2025-03-29 was $1.36B. Net income was $167.7M. Revenue was up 4.0% from 2024-03-30 to 2025-03-29. HAE currently screens at market cap $3.24B and trailing P/E 34.8.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
HAE currently screens at market cap $3.24B and trailing P/E 34.8. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the HAE and PATH stock pages for the full models.
Not investment advice.